December 20, 2012

Evolva successfully discussed clinical development plans for EV-077 in diabetes patients with German regulatory authority

Evolva Holding SA (SIX: EVE) today announces it has had a positive meeting with the German regulatory authority BfArM regarding the further clinical steps for EV- 077 (a novel, reversible antagonist of isoprostanes and prostanoids, in Phase IIa to treat vascular inflammation and complications of diabetes). Initial Phase IIa efficacy data have been published in August 2012.
PDF Download English Version
PDF Download German Version

read more »

December 14, 2012

Biotie: Selincro(TM) (nalmefene) receives positive opinion for approval in the European Union

Biotie today announced that its partner H.Lundbeck A/S (Lundbeck) has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending marketing authorization of Selincro(TM) (nalmefene; an opioid system modulator) for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high level of alcohol consumption. Once approved, Lundbeck will provide Selincro as part of a new treatment concept that includes continuous psychosocial support focused on the reduction of alcohol consumption and treatment adherence.
PDF Download

read more »

December 11, 2012

MerLion Pharmaceuticals Announces Initiation of first Phase II Clinical Study with Finafloxacin in Patients with Complicated Urinary Tract Infections

MerLion Pharmaceuticals (MerLion) announced today that it has initiated the first Phase II clinical trial using intravenous (iv) and oral formulations of finafloxacin to treat patients requiring hospitalisation with complicated urinary tract infections and pyelonephritis. Finafloxacin is a novel antibiotic that demonstrates unique acid activated activity and an outstanding safety profile, which differentiates it from existing antibiotic therapies and opens up exciting new treatment opportunities.
PDF Download

read more »

December 11, 2012

Biotie's tozadenant (SYN115) meets primary and multiple secondary endpoints in phase 2b study in Parkinson's disease

Biotie today reported top-line data from a Phase 2b study evaluating its adenosine A2a antagonist tozadenant (SYN115) in Parkinson's disease (PD) patients experiencing levodopa related end of dose wearing off. The study met its primary endpoint of a statistically highly significant decrease in 'off' time vs. placebo, as well as demonstrating efficacy across multiple secondary endpoints. Full data from the study will be disclosed at upcoming medical conferences and in scientific publications.
PDF Download

read more »

December 06, 2012

Omeros Announces Encouraging Data from Phase 1 Clinical Trial for PDE10 Program

Omeros Corporation (NASDAQ: OMER) today announced promising data from the single-ascending-dose (SAD) study portion of the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.  OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.
PDF Download

read more »

November 29, 2012

Evolva acquires resveratrol programme from Fluxome

Key highlights:
• Evolva acquires resveratrol – an on-market high value ingredient made by yeast fermentation
• Product expected to make a positive contribution to Evolva's cash flow starting 2014
• Consolidates Evolva strengths in yeast fermentation technologies and capabilities
• Non-binding investor commitment to fund resveratrol activities for next 18 months
• Transaction supports financing round - expected to complete Q1 2013
• Evolva streamlines portfolio – internal focus on vanilla/resveratrol and stevia/saffron pathways
PDF Download English Version
PDF Download German Version
 

read more »

November 15, 2012

GPR17-Targeting Compounds Identified by Omeros Promote Myelination

Omeros Corporation (NASDAQ: OMER) today announced that GPR17-targeting compounds, which were previously identified by Omeros in connection with unlocking this orphan receptor, have now been demonstrated to promote differentiation of the cells that form myelin in the central nervous system. Myelin is critical for the proper functioning of the nervous system, and demyelination is associated with multiple nervous system disorders, including multiple sclerosis (MS), traumatic brain or spinal cord injury, stroke and Alzheimer's disease.  Using its proprietary high-throughput Cellular Redistribution Assay, Omeros believes that it alone has identified compounds that interact with GPR17, an orphan G protein-coupled receptor (GPCR).
PDF Download

read more »

November 09, 2012

Omeros Corporation Reports Third Quarter 2012 Financial Results

Omeros Corporation (NASDAQ: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products targeting inflammation, coagulopathies and disorders of the central nervous system, today announced its financial results for the third quarter of 2012
PDF Download

read more »

November 07, 2012

MerLion Announces Successful Completion of a Phase I Clinical Study with Intravenously Administered Finafloxacin

Following successful first-in-man Phase I and two Phase IIa clinical studies with the oral formulation of finafloxacin, MerLion Pharmaceuticals Pte Ltd (MerLion) announces the completion of the first Phase I
study using an intravenous (iv) formulation of this highly differentiated antibacterial candidate.
PDF Download

read more »

November 01, 2012

Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824

Omeros Corporation (NASDAQ: OMER) today announced that the first subject has been enrolled in the Company's Phase 1 clinical trial evaluating OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program.  OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.  This Phase 1 dose-ranging study is evaluating the drug's safety, tolerability and pharmacokinetics in healthy subjects, and Omeros expects clinical data before year end.
PDF Download

read more »

October 24, 2012

Adding Four More, Omeros Has Now Unlocked 46 Orphan GPCRs

Omeros Corporation (NASDAQ: OMER) today announced that it has identified compounds that functionally interact with each of four additional orphan G protein-coupled receptors (GPCRs). Without compounds that functionally interact with orphan GPCRs, developing drugs targeting those receptors is extremely difficult. Omeros has now unlocked 46 Class A orphan GPCRs, representing almost 60 percent of these targets and equaling the number of GPCRs that are targeted by over 30 percent of all marketed drugs. There are approximately 120 orphan GPCRs and Omeros expects to unlock an even larger percentage of them, focusing first on Class A orphans.
PDF Download

read more »

October 22, 2012

Symetis ACURATE TF™ FIM Trial Completed

Symetis Inc., a private Swiss company developing new transcatheter aortic valve implantation (TAVI) systems, announced during the PCR London Valves meeting that it finished enrollment (n=20) in its First-In-Man (FIM) trial of the transfemoral aortic valve replacement device, the ACURATE TF™ Aortic Bioprosthesis and Delivery System.
PDF Download

read more »

October 15, 2012

European Commission awards EUR 6 million FP7 grant to support clinical development of NI-0501 to 'FIGHT HLH'

NovImmune announced that the European Commission has awarded a 6 million euro FP7 grant to the "FIGHT HLH" consortium of institutions to support clinical testing of NovImmune's anti-interferon gamma drug candidate, NI-0501.
PDF Download

read more »

October 04, 2012

RuiYi (formerly Anaphore) and arGEN-X Announce Exclusive Worldwide License Agreement for ARGX-109, a Novel anti-IL-6 Antibody

RuiYi (formerly Anaphore) and arGEN-X BV announced today that arGEN-X has granted a worldwide exclusive license to RuiYi to develop and commercialize ARGX-109, a novel anti-IL-6 monoclonal antibody discovered and developed by arGEN-X. Under the agreement, RuiYi will make an upfront payment to arGEN-X consisting of cash and equity. arGEN-X is also eligible to receive additional payments based on the achievement of certain clinical, regulatory and commercialization milestones and royalties based on worldwide net sales of therapeutic products.
PDF Download

read more »

October 04, 2012

Anaphore Announces Name Change to RuiYi and New Additions to Shanghai Management Team

Anaphore announced today that its corporate name has changed to RuiYi.  As part of the company’s shift in strategy to the discovery and development of novel biologic therapies in China, including monoclonal antibodies that target G protein coupled receptors (GPCRs), RuiYi has also added three seasoned leaders to its management team in Shanghai.
PDF Download

read more »

October 03, 2012

Omeros Announces Completion of Enrollment in OMS302 Phase 3 Clinical Trial

Omeros Corporation (NASDAQ: OMER) today announced that the last patient has been enrolled in the Company's second Phase 3 clinical trial evaluating OMS302 for use during intraocular lens replacement (ILR) surgery. OMS302, one of Omeros' proprietary PharmacoSurgery™ products, is added to standard irrigation solution used during ILR procedures to maintain intraoperative mydriasis (pupil dilation) and reduce postoperative pain. Maintenance of mydriasis is critical to the safety and surgical ease of the procedure, while intraoperative pupil constriction increases the risk of injury to intraocular structures and can substantially prolong surgical time.
PDF Download

read more »

October 02, 2012

Investigational New Drug Application Cleared for Omeros' Lead Compound in PDE10 Program

Omeros Corporation (NASDAQ: OMER) today announced that the Company's OMS824 Investigational New Drug Application (IND) has been cleared by the U.S. Food and Drug Administration (FDA). With this clearance, Omeros may commence enrollment in its Phase 1 clinical trial evaluating OMS824, the Company's lead compound from its phosphodiesterase 10 (PDE10) program for schizophrenia and other cognitive disorders.
PDF Download

read more »

September 28, 2012

Evolva reaches first milestone in Roquette collaboration

Evolva Holding SA (SIX: EVE) today announced that Roquette Frères SA (Roquette) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2012.
PDF Download English Version
PDF Download German Version

read more »

August 29, 2012

Evolva reports additional Phase IIa data on EV-077

Evolva Holding SA (SIX: EVE) today announces further data for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids. The data indicate that 300mg EV-077 given orally twice daily to patients with type 2 diabetes provided anti-platelet activity, reduced exercise-induced proteinuria and increased forearm blood flow. This was achieved with only a slight increase in bleeding time. The analysis also indicates that EV-077 was generally well tolerated, with adverse events mostly limited to increases in liver enzymes, which were transient or resolved after discontinuation.
PDF Download English Version
 

read more »

August 22, 2012

EBM and ewb take over 70-megawatt wind farms

The two utility companies EBM and Energie Wasser Bern (ewb) continue to expand their share of energy production from renewable sources. Through their joint venture company "leading swiss renewables AG" and with the support of Aravis they acquired a Spanish wind energy company which subsequently took over two wind farms with a total capacity of 70 megawatts(MW).
PDF Download English Version
PDF Download German Version

read more »

August 17, 2012

Evolva’s EV-077 achieved objectives in first group of patients in Phase IIa trial

Evolva Holding SA (SIX: EVE) today announced top-line results for the first 32 patients enrolled in the Phase IIa study of its investigational drug, EV-077, a novel, reversible antagonist of isoprostanes and prostanoids.

PDF Download English version
PDF Download German version

read more »

June 21, 2012

Evolva reaches first milestone in IFF collaboration

Evolva Holding SA (SIX: EVE) today announced that International Flavors & Fragrances Inc. (IFF) has confirmed that Evolva has achieved the first milestone in their collaboration that was announced in January 2011.
PDF Download English version
PDF Download German version

read more »

June 18, 2012

Ambrx Collaborates with Merck to Design and Develop Biologic Drug Conjugates

Ambrx today announced that the company has entered into a collaboration with Merck to design and develop rationally optimized biologic drug conjugates based on Ambrx’s site-specific protein medicinal chemistry technology.

PDF Download

read more »

May 14, 2012

Omeros entering NASDAQ Biotechnology Index

Click here to read the article.

read more »

April 19, 2012

Cell Therapeutics Enters into Agreement to Acquire Pacritinib, a Novel Highly Selective JAK2 Inhibitor Phase 3 Candidate for Myelofibrosis

Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) and S*BIO Pte Ltd announced today that the companies have entered into an asset purchase agreement.

PDF Download

read more »

April 18, 2012

MerLion Announces Initiation of a Phase III Clinical Programme to Evaluate Finafloxacin for the Treatment of Acute Otitis Media

MerLion Pharmaceuticals Pte Ltd (MerLion) announces the start of the first Phase III clinical trial to evaluate finafloxacin for treating infections of the ear.

PDF Download

read more »

March 22, 2012

Anaphore Announces Acquisition of RuiYi in Shanghai China for GPCR Biologics Drug Discovery Platform

Anaphore Inc. today announced that it has acquired Shanghai-based RuiYi Inc., bringing the company a powerful biologics drug discovery platform focused on the discovery and development of biologic therapies targeting G protein coupled receptors (GPCRs).
PDF Download

read more »

March 13, 2012

Omeros' Ophthalmology Product OMS302 Achieves Primary and Secondary Endpoints in Phase 3 Clinical Trial

Omeros Corporation (NASDAQ: OMER) today reported positive data from its Phase 3 clinical trial evaluating OMS302 in patients undergoing intraocular lens replacement surgery. OMS302 met its primary endpoint by demonstrating statistically significant (p<0.00001) maintenance of intraoperative mydriasis (pupil dilation). OMS302 also demonstrated statistical superiority (p<0.00001) over placebo in reduction of pain in the early postoperative period.

PDF Download

read more »

March 05, 2012

Evolva to present promising novel antibiotic at Superbugs & Superdrugs conference

Evolva Holding SA (SIX: EVE) today announced that Chief Scientific Officer Prof. Jutta Heim, will present data on Evolva’s promising novel antibiotic EV-035 at the conference “Superbugs & Superdrugs – A Focus on Antibacterials” in London on Monday 5 March 2012, at 1.45 PM (GMT).
PDF Download English Version
PDF Download German Version

read more »

February 29, 2012

Evolva successfully completes US biodefense program. Promising novel antibiotic to be presented at ASM

Evolva Holding SA (SIX: EVE) today announced that its project with the US Army Research Office (ARO), conducted as part of the Transformational Medical Technology Initiative’s mission to prevent and address biowarfare threats, has been completed successfully.
PDF Download English Version
PDF Download German Version

read more »

February 21, 2012

Biotie Courted by Potential Partners for Alzheimer’s Drug

Click here to read the article.

January 26, 2012

More power for renewable energy sources

EBM and ewb expedite the production of electricity from wind, small-scale hydro and solar power. For this purpose, these two energy providers have launched together with Aravis the Leading Swiss Renewables AG limited company. The new company will develop in the medium run as a leading producer and operator of renewable energy sources and establish itself as such in this market.

PDF Download English Version

PDF Download German Version

read more »

January 02, 2012

Evolva in collaboration with Roquette

Evolva Holding SA (SIX: EVE) today announced the signing of an agreement with Roquette Freres SA for joint research and development of novel and optimised biosynthetic production routes for an ingredient with important applications in food products. Roquette is a world leader in the area of nutrition and other products based on raw vegetable materials.

PDF Download English Version
PDF Download German Version

read more »